Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib with platelets ≥50 × 10⁹/L at treatment initiation: interim results from the MY-PAC study
NCODA Oncology and Hematology Meeting Abstracts · 2026
DOI: 10.67209/wpqr5260 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, 2026. Verfasst von Douglas Tremblay und 11 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Gefördert von: Sobi Inc..
Abstract (Originalsprache)
Pacritinib (PAC), a JAK1 sparing JAK2/IRAK1/ ACVR1 inhibitor is approved for patients with myelofibrosis (MF) and severe thrombocytopenia (platelet [PLT] counts
Förderung
- Sobi Inc.
Zitieren
APA
Tremblay, D., Oladapo, A., Levine, E., Marrone, M., Liassou, D., Suthar, P., Geprifti, A., Hoehn, G., Vredenburg, M., Feinberg, B., Pemmaraju, N., & Rossetti, J. (2026). Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib with platelets ≥50 × 10⁹/L at treatment initiation: interim results from the MY-PAC study. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/wpqr5260
Vancouver
Tremblay D, Oladapo A, Levine E, Marrone M, Liassou D, Suthar P, et al. Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib with platelets ≥50 × 10⁹/L at treatment initiation: interim results from the MY-PAC study. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/wpqr5260
BibTeX
@article{Tremblay2026,
author = {Tremblay, Douglas and Oladapo, Abiola and Levine, Emily and Marrone, Michael and Liassou, Djibril and Suthar, Purvi and Geprifti, Adina and Hoehn, Gerard and Vredenburg, Michael and Feinberg, Bruce and Pemmaraju, Naveen and Rossetti, James},
title = {Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib with platelets ≥50 × 10⁹/L at treatment initiation: interim results from the MY-PAC study},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/wpqr5260}
}
EUVIMED